Anti-CYR61/CCN1 antibody [EPR20681]
- 20ul selling size
- RabMAb
- Recombinant
- KO Validated
- What is this?
5
(1 Review)
|
(8 Publications)
Rabbit Recombinant Monoclonal CYR61/CCN1 antibody. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 8 publications.
View Alternative Names
CYR61, GIG1, IGFBP10, CCN1, CCN family member 1, Cellular communication network factor 1, Cysteine-rich angiogenic inducer 61, Insulin-like growth factor-binding protein 10, Protein CYR61, Protein GIG1, IBP-10, IGF-binding protein 10, IGFBP-10
- ICC/IF
Supplier Data
Immunocytochemistry/ Immunofluorescence - Anti-CYR61/CCN1 antibody [EPR20681] (AB230947)
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized MDA-MB-231 (human breast adenocarcinoma epithelial cell) cells labeling CYR61/CCN1 with ab230947 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic staining in the MDA-MB-231 cell line. Negative control : MCF7 (PMID : 11059746). The nuclear counter stain is DAPI (blue).
Counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at a 1/200 dilution (red).
The negative control is the secondary antibody only.
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-CYR61/CCN1 antibody [EPR20681] (AB230947)
Intracellular flow cytometric analysis of 4% paraformaldehyde-fixed, 90% methanol permeabilized MCF7 (human breast adenocarcinoma epithelial cell, Left) / MDA-MB-231 (human breast adenocarcinoma epithelial cell, Right) cell line labeling CYR61/CCN1with ab230947 at 1/60 (red) compared with a Rabbit monoclonal IgG (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat anti rabbit IgG (Alexa Fluor� 488, ab150077), at 1/2000 dilution was used as the secondary antibody.
Negative control : MCF7 (PMID : 11059746).
- IP
Unknown
Immunoprecipitation - Anti-CYR61/CCN1 antibody [EPR20681] (AB230947)
CYR61/CCN1 was immunoprecipitated from 0.35 mg Saos-2 (human osteosarcoma epithelial) whole cell lysate with ab230947 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab230947 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.
Lane 1 : Saos-2 (human osteosarcoma epithelial) whole cell lysate 10 μg (Input).
Lane 2 : ab230947 IP in Saos-2 whole cell lysate (+).
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab230947 in Saos-2 whole cell lysate (-).
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 8 seconds.
The molecular mass observed is consistent with that of the full-length protein (42 kDa) (PMID : 23798676).
All lanes:
Immunoprecipitation - Anti-CYR61/CCN1 antibody [EPR20681] (ab230947)
Predicted band size: 42 kDa
false
- WB
Supplier Data
Western blot - Anti-CYR61/CCN1 antibody [EPR20681] (AB230947)
Blocking/ Dilution buffer concentration : 5% NFDM/TBST.
The molecular mass observed is consistent with that of the full-length protein (42 kDa) (PMID : 23798676).
All lanes:
Western blot - Anti-CYR61/CCN1 antibody [EPR20681] (ab230947) at 1/5000 dilution
All lanes:
MDA-MB-231 (human breast adenocarcinoma epithelial cell), whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 42 kDa
Observed band size: 42 kDa
false
Exposure time: 3min
- WB
Lab
Western blot - Anti-CYR61/CCN1 antibody [EPR20681] (AB230947)
Lanes 1-4 : Merged signal (red and green). Green - ab230947 observed at 47 kDa. Red - loading control ab8245 observed at 36 kDa.
ab230947 Anti-CYR61/CCN1 antibody [EPR20681] was shown to specifically react with CYR61/CCN1 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265288 (knockout cell lysate ab257406) was used. Wild-type and CYR61/CCN1 knockout samples were subjected to SDS-PAGE. ab230947 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-CYR61/CCN1 antibody [EPR20681] (ab230947) at 1/500 dilution
Lane 1:
Wild-type HeLa cell lysate at 20 µg
Lane 2:
CYR61 knockout HeLa cell lysate at 20 µg
Lane 2:
Western blot - Human CYR61 (CCN1) knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-cyr61-ccn1-knockout-hela-cell-line-ab265288'>ab265288</a>)
Lane 3:
MDA-MB-231 cell lysate at 20 µg
Lane 4:
MCF7 cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution
Predicted band size: 42 kDa
Observed band size: 47 kDa
false
- WB
Supplier Data
Western blot - Anti-CYR61/CCN1 antibody [EPR20681] (AB230947)
Blocking/Dilution buffer concentration : 5% NFDM/TBST.
The expression profile observed is consistent with the literature, with the 42 kDa band being the full-length protein and the 19 kDa band likely a degradation product (PMID : 23798676; PMID : 16266990; PMID : 8657105).
Negative control : MCF7 (PMID 11059746).
All lanes:
Western blot - Anti-CYR61/CCN1 antibody [EPR20681] (ab230947) at 1/1000 dilution
Lane 1:
PC-3 (human prostate adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2:
Saos-2 (human osteosarcoma epithelial) whole cell lysate at 20 µg
Lane 3:
MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 42 kDa
false
Exposure time: 3min
Related conjugates and formulations (1)
-
Anti-CYR61/CCN1 antibody [EPR20681] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The CYR61/CCN1 protein acts as a signaling molecule that influences cell proliferation migration and adhesion. It interacts with integrins and heparan sulfate proteoglycans on the cell surface facilitating cellular communication that is essential for structural and functional tissue integrity. Additionally CYR61 is a part of multiprotein complexes impacting angiogenesis and inflammation. These activities place CYR61/CCN1 at a pivotal point in wound healing and vascularization processes.
Pathways
The CYR61/CCN1 protein participates in key signaling pathways such as the MAPK/ERK and Wnt pathways. These pathways modulate gene expression related to cell growth and differentiation. CYR61 collaborates with other proteins including VEGF and FGF to regulate cardiovascular development and morphogenesis. The interaction with these pathways highlights the protein’s integral role in cellular homeostasis and response to physiological changes.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (8)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in oncology 15:1528288 PubMed40786514
2025
Applications
Unspecified application
Species
Unspecified reactive species
Neoplasia (New York, N.Y.) 60:101102 PubMed39674114
2024
Applications
Unspecified application
Species
Unspecified reactive species
Biomedicines 11: PubMed36979893
2023
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 23: PubMed36142828
2022
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 26: PubMed36102309
2022
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in bioscience (Landmark edition) 26:1411-1421 PubMed34994156
2022
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 24: PubMed34396425
2021
Applications
Unspecified application
Species
Unspecified reactive species
Stem cell research & therapy 10:179 PubMed31215503
2019
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com